Crinecerfont Patent Expiration
Crinecerfont was first introduced by Neurocrine Biosciences Inc
Crinecerfont Patents
Given below is the list of patents protecting Crinecerfont, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Crenessity | US12582634 | Synthetic Methods For Preparation Of 4-(2-Chloro-4-Methoxy-5-Methylphenyl)-N-[(1S)-2-Cyclopropyl-1-(3-Fluoro-4-Methylphenyl)Ethyl]-5-Methyl-N-Prop-2-Ynyl-1,3-Thiazol-2-Amine | Jan 12, 2043 | Neurocrine |
| Crenessity | US12128033 | Synthetic methods for preparation of 4-(2-chloro-4-methoxy-5-methylphenyl)-n-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-n-prop-2-ynyl-1,3-thiazol-2-amine | Jun 09, 2041 | Neurocrine |
| Crenessity | US10905690 | Treatment of congenital adrenal hyperplasia | Jan 21, 2035 | Neurocrine |
| Crenessity | US11311544 | Treatment of congenital adrenal hyperplasia | Jan 21, 2035 | Neurocrine |
| Crenessity | US11730739 | Treatment of congenital adrenal hyperplasia | Jan 21, 2035 | Neurocrine |
Crinecerfont's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Crinecerfont:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Crinecerfont in Participants With Classic Congenital Adrenal Hyperplasia (CAH) Who Are Less Than 4 Years Old | Neurocrine Switzerland GmbH | NA |
RECRUITING
(Sep 1, 2026)
| PHASE2 |
| Pharmacokinetics, Safety and Tolerability of Crinecerfont in Participants With Congenital Adrenal Hyperplasia Who Are Less Than 2 Years Old | Neurocrine Switzerland GmbH | NA |
ACTIVE NOT RECRUITING
(Aug 1, 2026)
| PHASE2 |
| Global Safety and Efficacy Registration Study of Crinecerfont for Congenital Adrenal Hyperplasia | Neurocrine Biosciences | NA |
ACTIVE NOT RECRUITING
(Apr 1, 2026)
| PHASE3 |